Who is behind ARGEA
ARGEA is a treatment programme built around an enzyme we develop ourselves. NGA-8000 comes from our own biotech laboratory; treatment is given by licensed physicians at partner clinics. More than 100 patients have been treated with NGA-8000 through the programme and its partner physicians. It brings together our own biotech laboratory, treating physicians and a small coordinating team, with one job: to make arginine deprivation available to individual patients safely, honestly and with full records.
Martin Wyss, PhD
Leads the programme. Responsible for the laboratory programme behind NGA-8000, patient coordination, the standards on this site and the written disclosure every patient receives. Your first and last point of contact.
contact@argea.health
Oncologists and internists at partner clinics
There is no single treating physician. Each patient is assigned to physicians according to tumour type, language and the clinic where treatment takes place; a leukaemia patient and a patient with pancreatic cancer are not seen by the same specialist. What they have in common: a licence to practise, specialist training in oncology or internal medicine, and experience with the enzyme. They review eligibility, lead the disclosure consultation, administer the therapy and sign every review. They are named to you in writing before consent, together with their qualifications and licence numbers.
Care team
Nursing and coordination staff at the partner clinic handle your weekly visits, your results and your questions between visits. You get one contact number that is answered by a person who knows your case.
WYSS PERFORMANCE LLC-FZ
ARGEA is a programme of WYSS PERFORMANCE LLC-FZ, a free-zone company registered in Dubai, United Arab Emirates. The company coordinates the programme, holds the contracts with patients and partners, and is responsible for this website.